The effect of nutritional status on protective efficacy of a live attenuated human rotavirus vaccine (RIX4414) was studied. Vaccine protection was evaluated through a secondary analysis of data from an efficacy study conducted in Brazil, Mexico, and Venezuela. Vaccine efficacy against rotavirus gastroenteritis (RVGE) was similar in well-nourished and malnourished infants: 74.1% (95% confidence interval [CI], 52.2%-86.2%) and 73% (95% CI, 11.2%-92.3%) for severe RVGE and 60.9% (95% CI, 37.4%-75.4%) and 61.2% (95% CI, 10.4%-83.1%) for RVGE of any severity, respectively. RIX4414 significantly decreased the rate of RVGE regardless of nutritional status, which suggests that this patient group can also benefit from rotavirus vaccination.
licensed in 180 countries is the live attenuated human rotavirus vaccine (RIX4414) containing the G1P [8] strain [2] that was developed from the parent vaccine strain 89-12 [3] . In phase II and III efficacy and safety trials, RIX4414 vaccine was shown to be well tolerated and immunogenic while providing broad cross-protection against other nonvaccine strains [4, 5] .
Malnutrition is a common and well-recognized public health problem in developing countries [6, 7] . It has also been associated with a high proportion of hospitalizations and deaths caused by diarrhea [7, 8] . In addition, it has been described that an impaired nutritional condition affects the immune system [9] . As a consequence, the interaction between nutrition and the immune system could interfere with the efficacy of rotavirus immunization, a phenomenon that had been described for another rotavirus (rhesus rotavirus tetravalent vaccine [RRV-TV]) candidate vaccine [10] . To determine whether malnutrition affects the efficacy of RIX4414 vaccine, a secondary analysis of data from the efficacy study was conducted in Brazil, Mexico, and Venezuela [4] . The results of that analysis are presented here.
Materials and methods. The methodology of the phase II study conducted in Belém (Brazil), Mexico City (Mexico), and Valencia (Venezuela) has been described elsewhere [4] . Briefly, healthy full-term infants (gestational age, 36-42 weeks), who weighed 12000 g at birth and who were 6-12 weeks (42-90 days) old at the time of the first vaccination, and whose parent or legal guardian signed an informed consent form were enrolled to receive 2 oral doses of the RIX4414 vaccine (GlaxoSmithKline Biologicals) or placebo according to a 0, 2-month schedule. Three concentrations (10 4.7 , 10 5.2 , and 10 5.8 focusforming units [ffu]) of RIX4414 were tested. Routine childhood vaccines were administered (diphtheria-tetanus toxoid-wholecell pertussis, Haemophilus influenzae type b, and hepatitis B virus) concomitantly with each study vaccine dose. Oral poliovirus vaccine was given at least 14 days before or after administration of study vaccine. The study was approved by the ethics committee of each study center and was conducted according to good clinical practice guidelines and the 1996 version of the Declaration of Helsinki.
All vaccinated infants were actively monitored for the occurrence of acute gastroenteritis episodes through weekly visits by health care workers starting from the administration of dose 1 until they were 1 year old, as described elsewhere [4] . Gastroenteritis was defined as diarrhea characterized by у3 looser than normal stools within a 24-h period. The widely accepted Ruuska and Vesikari 20-point scoring system was used to grade the severity of rotavirus gastroenteritis episodes [4] . An episode with a score of р6 was defined as mild, 7-10 as moderate, and у11 as severe [4] .
Stool specimens were collected within 7 days of the onset of diarrhea and were first tested for rotavirus using ELISA [4] at the laboratory of Dr. R. Ward, Children's Hospital Medical Center (Cincinnati, OH). All rotavirus-positive specimens were tested by reverse-transcription polymerase chain reaction at GlaxoSmithKline Biologicals (Rixensart, Belgium) for determination of the G type [4] . All G1 rotaviruses detected until 2 months after the second dose were analyzed to differentiate between vaccine and wild-type G1 strains.
Demographic data collected during the study included information about weight and age at each study visit. Information on feeding (breast milk or instant formula) was collected on the day of each vaccine/placebo administration. There were no restrictions on feeding the infants before or after vaccine/placebo administration. Nutritional status of the infants at the time of dose 1 was assessed by using World Health Organization growth charts weight for age (for both girls and boys) based on the following criterion: infants presenting a weight for age equal to or below the 10th percentile in the growth curve were considered to be malnourished [11] . Malnutrition was categorized by low weight for age into 3 groups as follows: mild (between the 10th percentile and Ϫ3.00 SD in the curve), moderate (Ϫ3.01 to Ϫ4.00 SD), and severe (!Ϫ4.01 SD). Vaccine efficacy (VE) according to nutritional status (well nourished and malnourished) and 95% confidence intervals (CIs) were calculated in the according-to-protocol (ATP) efficacy cohort as described elsewhere [3] . The ATP efficacy cohort included infants who did not receive a vaccine forbidden by or not specified in the protocol; who tested negative for rotavirus antigen on the day of the first dose of study vaccine or placebo; who received 2 doses of study vaccine or placebo according to the protocol; who had no randomization code broken; who had no rotavirus other than vaccine strain in stool samples collected from first dose until 2 weeks after the second dose; and who entered the surveillance period and had follow-up data 115 days after the second dose. The 2-sided Fisher's exact test (5% significance level) was used to compare rates between groups.
Results. When we examined the weight for age at dose 1 for the 1846 infants (1392 in the pooled vaccine group and 454 in the placebo group) included in the primary efficacy analysis, we observed that 287 infants fulfilled the criteria for malnutrition and 1559 infants were considered to be well nourished. The distribution of infants by group (vaccine or placebo) and nutritional condition was 1181 pooled vaccinees and 378 placebo recipients in the well-nourished group and 211 pooled vaccinees and 76 placebo recipients in the malnourished group. All malnourished infants were categorized as being mildly malnourished. The majority of well-nourished and malnourished infants was exclusively breast-fed or breast-fed complemented with infant formula. At the first dose, 96.7% of well-nourished and 93.4% of malnourished infants were breast-fed or breastfed complemented with infant formula. At the second dose, 91% of well-nourished and 84.3% of malnourished infants were breast-fed or breast-fed complemented with infant formula. Tables 1 and 2 present VEs in the ATP cohort against all and severe rotavirus gastroenteritis (RVGE) according to the nutritional status of subjects. In the pooled vaccine groups, severe RVGE was reported in 2.8% (6/211) of malnourished infants and in 2% (21/1181) of well-nourished infants; RVGE of any severity was reported in 6.6% (14/211) of malnourished infants and in 3.7% (44/1181) of well-nourished infants. In the placebo group, severe RVGE was reported in 10.5% (8/76) of malnourished and in 6.9% (26/378) of well-nourished infants. Among the placebo and vaccine recipients, the incidence of RVGE was higher in malnourished infants but was not statistically significant ( ). The majority of RVGE episodes in P 1 .05 both well-nourished and malnourished infants were caused by G1P [8] strain, and G9P [8] was the second most prevalent RV strain. In well-nourished placebo recipients, G1 wild-type rotavirus was identified in 51% and G9 type in 35% of observed RVGE episodes. Seventy-nine percent of RVGE episodes reported in malnourished infants receiving placebo were caused by G1 wild-type rotavirus and 14% by G9 type. VE against severe or all RVGE was similar in well-nourished and malnourished infants: 74.1% (95% CI, 52.2%-86.2%) and 73% (95% CI, 11.2%-92.3%) against severe RVGE and 60.9% (95% CI, 37.4%-75.4%) and 61.2% (95% CI, 10.4%-83.1%) against any RVGE, respectively. Of interest, VE was the highest in the group receiving the highest concentration (actually commercially available formulation) of RIX4414 strain in all cases, particularly in malnourished infants (92%-100%) (tables 1 and 2).
Discussion. Malnutrition is an underlying cause of childhood deaths [6, 7] . In trying to achieve a breakthrough for the control of infectious disease mortality, the synergy that exists between malnutrition and infectious disease should be reduced. This synergy has been most clearly demonstrated for diarrheal illness [7, 12] ; diarrhea precipitates and accelerates the progression of malnutrition, which increases the duration of diarrhea and lessens resistance. Because rotavirus has been described as the most common cause of diarrheal disease worldwide and given the availability of rotavirus vaccines with good efficacy and safety profiles [1, 2] , a positive impact to reduce this synergy is now a possibility. However, given the fact that malnutrition is common, it is important to evaluate whether malnutrition affects the efficacy of rotavirus vaccine, given that it has previously been reported that malnutrition may interfere with the efficacy of another rotavirus (RRV-TV) vaccine candidate [10] .
To evaluate the effect of nutritional status on protective efficacy of a live attenuated human rotavirus vaccine (RIX4414), a secondary analysis of data from the efficacy study conducted in Brazil, Mexico, and Venezuela was completed. In this study, VE against RVGE was similar among well-nourished and malnourished infants: 74% and 73% against severe RVGE and 61% for both against RVGE of any severity. These results were very similar to the protection rates against severe RVGE and RVGE of any severity for pooled vaccine groups reported for the complete original study cohort: 74% (95% CI, 56%-85%) and 61% (95% CI, 42%-74%), respectively [4] . It is also relevant to note that the VE was the highest in all infants vaccinated with the highest concentration (10 5.8 ffu), which is the viral titer contained in the commercially available vaccine, and that the VE was particularly high in malnourished infants (92%-100%). These findings are in contrast to the results of the RRV-TV rotavirus vaccine study [10] . This may be due to the low number of malnourished infants evaluated in that study.
At the same time, this RIX4414 study reminds us that malnutrition increases the severity of diarrheal disease [12] . The attack rate of severe RVGE was higher, although not statistically significant, in malnourished than in well-nourished children (10.5% vs. 6.9% in the respective placebo groups). The worldwide introduction of a rotavirus vaccine may therefore be par-ticularly beneficial to children with malnutrition. Although it is likely that such a difference may have occurred by chance, one could argue that a trend toward higher efficacy among malnourished children may be related to the fact that they usually have more severe diarrhea and it is largely recognized that rotavirus vaccines induce a greater protection against severe than against mild/moderate diseases. Our data for the placebo group, however, show that there was not significant difference in proportions of severe RVGE (Vesikari scale score у11) between malnourished and well-nourished children.
Our results show that malnutrition did not seem to influence efficacy of the rotavirus vaccine (RIX4414), which confirms the lack of a firm association between malnutrition and the overall response to immunization [13, 14] . Moreover, malnourished children, who are more vulnerable to die of diarrhea, should be a prime focus for immunization programs to reduce the burden of severe rotavirus diarrheal disease. It should be noted that the present findings are limited to only the mild cases of malnutrition observed in our study.
More data to validate these results in areas with more severe malnourished children are needed. The planned development of clinical trials in the populations of Asia and Africa may present an opportunity to further evaluate the question of malnutrition and efficacy of RIX4414 (Rotarix; GlaxoSmithKline) vaccine.
